“Proton Partners is delighted to be partnering with IBA and Royal Philips in bringing innovative proton beam therapy to the Middle East” said Mike Moran, Chief Executive Officer of Proton Partners International. “We are the UK’s leading developer of proton beam therapy facilities and we are currently developing three centers across the UK, with two others being planned. Our long-term vision is to build seven UK centers and five international centers which will make Proton Partners the world’s largest operator of proton beam therapy.
“We are now fully established in the Gulf International Cancer Center in Abu Dhabi. Conventional treatments are currently on offer, such as chemotherapy, traditional radiotherapy, diagnostics and counselling, and we expect proton beam therapy to be available from January 2019. Cancer incidence is rising dramatically globally and more innovation is needed to deal with this disease. We envisage this development will put the UAE in the frontline of cancer treatment and research and look forward to building on our strong relationship with IBA and Royal Philips.”
*Proteus®ONE and Proteus®PLUS are the brand names of the Proteus®235.
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solution. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.
Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com.
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips’ wholly owned subsidiary Philips Lighting is the global leader in lighting products, systems and services. Headquartered in the Netherlands, Philips posted 2015 sales of EUR 24.2 billion and employs approximately 105,000 employees with sales and services in more than 100 countries.
